A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer

Tumori

Volumn 93, Issue 3, 2007, Pages 244-247

  Dalla Chiesa, Matteo ^a   Buti, Sebastiano ^a   Tomasello, Gianluca ^a   Negri, Federica ^a   Buononato, Massimo ^a   Brunelli, Antonio ^a   Lazzarelli, Silvia ^a   Brighenti, Matteo ^a   Donati, Gianvito ^a   Passalacqua, Rodolfo ^a  

^a CREMONA HOSPITAL   (Italy)

Author keywords

5 fluorouracil; Folinic acid; Irinotecan; Metastatic gastric cancer; Oxaliplatin

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; FLUOROURACIL TEVA; FOLINIC ACID; IRINOTECAN; LEVOFOLENE; OXALIPLATIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 34447555858     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300303     Document Type: Article

References (13)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB: Cancer incidence in five Continents (volume VIII). Lyon, France, International Agency for Research on Cancer, 2002.
2. Kohne CH, Wils JA, Wilke HJ: Developments in the treatment of gastric cancer in Europe. Oncology, 14: 22-25, 2000.
3. Wils JA, Klein HO, Wagener H, Bleiberg H, Reis H, Korsten F, Conroy Th, Fickers M, Leyvraz S, Buyse M, Duez N, for the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol, 9: 827-831, 1991.
4. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V, Luppi G, Mazzocchi B, Rodino C, Soldani M: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol, 12: 2687-2693, 1994.
5. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, Bisagni G, Porrozzi S, Cognetti F, Di Costanzo F, Cataletti R, Ruggeri EM, Camisa R, Pucci F: Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol, 14: 1258-1263, 2003.
6. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 80: 269-272, 1999.
7. Vanhofer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 18: 2648-2657, 2000.
8. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, François E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A: Phase II Study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol, 20: 4543-4548, 2002.
9. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier F, Bedenne L, Milan C: Randomized multicenter phase ii trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Fédération Francophone de Cancérologie Digestive Group Study-FFCD 9803. J Clin Oncol, 22: 4319-4328, 2004.
10. Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, Kramar A: An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol, 14: 481-489, 2003.
11. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol, 20: 4006-4014, 2002.
12. Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G: Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study. J Clin Oncol, 20: 1228-1236, 2005.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.